RESUMO
Despite the clinical acceptance of ToF-PET, there is still a gap between the technology's performance and the end-user's needs. Core to bridging this gap is the ability to develop radiation detectors combining a short attenuation length and a sub-nanosecond time response. Currently, the detector of choice, Lu2SiO5:Ce3+ single crystal, is not selected for its ability to answer the performance needs, but as a trade-off between requirements and availability. To bypass the current performance limitations, in particular restricted time response, the concept of the heterostructured detector has been proposed. The concept aims at splitting the scintillation mechanisms across two materials, one acting primarily as an absorber and one as an ultra-fast emitter. If the concept has attracted the interest of the medical and material communities, little has been shown in terms of the benefits/limitations of the approach. Based on Monte Carlo simulations, we present a survey of heterostructure performance versus detector design. The data allow for a clear understanding of the design/performance relationship. This, in turn, enables the establishment of design rules toward the development and optimization of heterostructured detectors that could supersede the current detector technology in the medical imaging field but also across multiple sectors (e.g. high-energy physics, security).
RESUMO
GenesFX Health (Melbourne, Australia) is providing genetic testing with clinical interpretation to personalize how people take medications. The company's aim is to achieve the best health outcomes for patients by ensuring that the way they metabolize medications is included when doctors prescribe them medication. This would be achieved by introducing pharmacogenomics into medical practice to provide more informed prescribing, reduce side effects and create maximum efficacy of medications. Through the use of GenesFX Health innovative genetic test, DNAdose®, GenesFX Health is able to analyze the profile of a patient's genetic variation and maps this to the optimum drug and dosage for a specific treatment. The company's focus on the interpretation of genetic test results has led to the development of a Pharmacogenomic Database and Pharmacogenomic Interpretation System, which allows the team to communicate complex genetic test results in a meaningful way to doctors. There is a significant opportunity to expand GenesFX Health current model of delivering pharmacogenomic tests, by partnering with other laboratories around the world, making pharmacogenomics more accessible and clinically useful. Doctors using the service have welcomed the clinical guidance. Patients have felt relieved and empowered by understanding why they have adverse reactions to medications, and which medications and doses are most suited to them.